AR012340A1 - 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen - Google Patents

3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen

Info

Publication number
AR012340A1
AR012340A1 ARP980101558A ARP980101558A AR012340A1 AR 012340 A1 AR012340 A1 AR 012340A1 AR P980101558 A ARP980101558 A AR P980101558A AR P980101558 A ARP980101558 A AR P980101558A AR 012340 A1 AR012340 A1 AR 012340A1
Authority
AR
Argentina
Prior art keywords
substituted
dihydro
useful
nr5r5a
reverse transcriptase
Prior art date
Application number
ARP980101558A
Other languages
English (en)
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of AR012340A1 publication Critical patent/AR012340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion hace conocer 3,4-dihidro-2(1H)-quinazolinonas 4,4- disustituidas de la formula (I), o las formas estereoisoméricas, mezclasestereoisoméricas o sales apras para uso farmacéutico de las mismas, que son de utilidad como inhibidores de la transcriptasa inversa del HIV y concomposiciones farmacéuticas y kits de diagnostico que contienen a las mismas, donde: R1 es alquilo-C1-3 sustituido con 1-7 halogenos; R2 se selecciona dealquilo-C1-5 sustituido con 1-2 R4, alquenilo-C2-5 sustituido con 1-2 R4 y alquinilo-C2-5 sustituido con 1 R4; R3, en cada aparicion, se seleccionaindependientemente de alquilo-C1-4, OH, alcoxi-C1-4, F, Cl, Br, I, NR5R5a, NO2, CN, C(O)R6, NHC(O)R7 y NHC(O)NR5R5a, como alternativa, si hay dosR3 yestán unidos a átomos de carbono adyacentes, entonces se pueden combinar para formar -OCH2O-; R4 se selecciona de cicloalquilo-C3-5 sustituido con 0-2 R3,fenilo sustituido con 0-5 R3 y un sistema heterocíclico de 5-6 miembros que contienede 1-3 heteroátomos seleccionados entre O, N y S, sustituido con 0-2R3; R5 y R5a se seleccionan independientemente de H y alquilo C1-3; R6 se selecciona de H, OH, alquilo C1-4, alcoxi-C1-4, y NR5R5a; R7 se selecciona dealquilo C1-3 y alcoxi-C1-3; R8 se selecciona de H, cicloalquilo-C3-5 y alquilo C1-3 y n se selecciona de 0, 1, 2, 3 y 4.
ARP980101558A 1997-04-09 1998-04-06 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen AR012340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US7132298P 1998-01-14 1998-01-14

Publications (1)

Publication Number Publication Date
AR012340A1 true AR012340A1 (es) 2000-10-18

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101558A AR012340A1 (es) 1997-04-09 1998-04-06 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen

Country Status (19)

Country Link
EP (1) EP0973753A2 (es)
JP (1) JP2002504095A (es)
KR (1) KR20010006146A (es)
CN (1) CN1252063A (es)
AR (1) AR012340A1 (es)
AU (1) AU734928B2 (es)
BR (1) BR9808513A (es)
CA (1) CA2284996A1 (es)
EA (1) EA001991B1 (es)
EE (1) EE9900452A (es)
HR (1) HRP980143A2 (es)
HU (1) HUP0001446A3 (es)
IL (1) IL132188A0 (es)
NO (1) NO314936B1 (es)
NZ (1) NZ500592A (es)
PL (1) PL336305A1 (es)
SK (1) SK137899A3 (es)
TW (1) TW587078B (es)
WO (1) WO1998045276A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322203A1 (en) * 1998-03-27 1999-10-07 Jeffrey W. Corbett 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
WO2000021565A1 (en) 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
HRP990358A2 (en) * 1998-11-19 2000-08-31 Du Pont Pharm Co Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1h)-quinazolinone
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
DE60023025T2 (de) * 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
CA2403230A1 (en) * 2000-03-23 2001-09-27 Lilian A. Radesca Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7198606B2 (en) 2002-04-19 2007-04-03 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2004060370A1 (en) * 2002-12-16 2004-07-22 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc METHOD AND APPARATUS FOR PROVIDING IMPROVED SAMPLE CAPTURING DEVICE
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND APPARATUS PROVIDING A VARIABLE USER INTERFACE
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
AP2013007166A0 (en) * 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
JP6373978B2 (ja) 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
PT3004108T (pt) 2013-05-28 2018-01-24 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
JP6403761B2 (ja) 2013-05-28 2018-10-10 ノバルティス アーゲー ピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
JP2016537384A (ja) 2013-11-21 2016-12-01 ノバルティス アーゲー ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
HUT71401A (en) * 1992-05-07 1995-11-28 Merck & Co Inc New quinazolines as inhibitors of hiv reverse transcriptase
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
HRP980143A2 (en) 1999-02-28
JP2002504095A (ja) 2002-02-05
EA001991B1 (ru) 2001-10-22
CA2284996A1 (en) 1998-10-15
HUP0001446A2 (hu) 2001-05-28
BR9808513A (pt) 2000-05-23
CN1252063A (zh) 2000-05-03
NO994904L (no) 1999-12-01
HUP0001446A3 (en) 2001-11-28
KR20010006146A (ko) 2001-01-26
WO1998045276A2 (en) 1998-10-15
WO1998045276A3 (en) 1999-01-14
AU734928B2 (en) 2001-06-28
EA199900907A1 (ru) 2000-04-24
PL336305A1 (en) 2000-06-19
IL132188A0 (en) 2001-03-19
EP0973753A2 (en) 2000-01-26
SK137899A3 (en) 2000-05-16
EE9900452A (et) 2000-04-17
TW587078B (en) 2004-05-11
AU6796098A (en) 1998-10-30
NZ500592A (en) 2001-09-28
NO314936B1 (no) 2003-06-16
NO994904D0 (no) 1999-10-08

Similar Documents

Publication Publication Date Title
AR012340A1 (es) 3,4-dihidro-2(1h)-quinazolinonas 4,4-disustituidas utiles como inhibidores de la transcriptasa inversa del hiv, composicion y kitfarmaceuticos que las contienen
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
PA8551001A1 (es) Nuevos compuestos
CO5600998A2 (es) Fluoropirrolidinas como inhibidores de dipeptidil peptidasa
HUP0203450A2 (hu) Pirazolo[4,3-d]pirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
CO5580747A2 (es) Derivados e intermediarios de n-adamantilmetilo como composiciones farmaceuticas y procesos para su preparacion
AR023659A1 (es) Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
BR0012646A (pt) Composto, análogo de oligonucleotìdeo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um análogo de oligonucleotìdeo
HRP20000896B1 (en) Adenosine derivatives
AR071043A1 (es) Acido l -glutamico marcado con (f -18), l- glutamina marcada con (f-18), sus derivados y su uso, asi como procedimientos para su preparacion
ES2087721T3 (es) Guanidinas sustituidas con (benzodioxano, benzofurano o benzopirano)-alquilamino-alquilo como vasoconstrictores selectivos.
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
PE58599A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
PE20011349A1 (es) 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
CO5050264A1 (es) Derivados de 6-azauracilo como inhibidores il-5 procedimientos para su preparacion y composiciones farmaceuticas que comprenden dichos derivados
AR054418A1 (es) Quinazolinas pirazolamino sustituidas. procesos de obtencion y composiciones farmaceuticas.
AR052663A1 (es) Compuestos de oxima heterociclicos, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CL2021002475A1 (es) Formulaciones fungicidas con crecimiento reducido de cristales.
RU2004130284A (ru) Антипаразитарные производные артемизинина (эндопероксиды)
AR001995A1 (es) Derivados de bencisoxazol, procedimientos para su manufactura, agentes antiparasitarios que los contienen como ingredientes activos y procedimientospara el control de microorganismos fitopatogenicos, insectos y acaros.
AR039425A1 (es) Compuestos de o-eter de oxima, procesos para su preparacion y fungicidas para uso en la agricultura y horticultura
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal